Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. monthly Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-15.53 Insider Own2.90% Shs Outstand24.04M Perf Week6.36%
Market Cap2.55B Forward P/E- EPS next Y-14.90 Insider Trans-6.06% Shs Float17.64M Perf Month-6.16%
Income-381.00M PEG- EPS next Q-3.72 Inst Own84.60% Short Float27.71% Perf Quarter-30.06%
Sales11.60M P/S219.76 EPS this Y29.90% Inst Trans1.05% Short Ratio10.55 Perf Half Y-26.80%
Book/sh16.77 P/B6.32 EPS next Y4.70% ROA-58.90% Target Price190.94 Perf Year-30.14%
Cash/sh32.44 P/C3.27 EPS next 5Y7.00% ROE-79.30% 52W Range89.76 - 177.93 Perf YTD-29.00%
Dividend- P/FCF- EPS past 5Y-59.20% ROI-38.10% 52W High-40.40% Beta-2.09
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low18.14% ATR6.16
Employees405 Current Ratio14.60 Sales Q/Q1063.40% Oper. Margin- RSI (14)42.63 Volatility4.39% 5.24%
OptionableYes Debt/Eq0.81 EPS Q/Q-70.80% Profit Margin- Rel Volume0.95 Prev Close102.74
ShortableYes LT Debt/Eq0.81 EarningsNov 03 BMO Payout- Avg Volume463.19K Price106.04
Recom2.30 SMA20-2.46% SMA50-14.79% SMA200-24.93% Volume439,970 Change3.21%
Aug-05-16Downgrade Laidlaw Buy → Sell $345 → $105
Jul-06-16Initiated Cantor Fitzgerald Sell $58
Jun-01-16Reiterated Wedbush Outperform $423 → $239
Apr-08-16Downgrade Morgan Stanley Equal-Weight → Underweight
Apr-05-16Upgrade Wells Fargo Market Perform → Outperform
Mar-30-16Initiated Goldman Neutral
Mar-30-16Initiated Credit Suisse Outperform $200
Feb-24-16Reiterated Wedbush Outperform $493 → $423
Dec-04-15Initiated Wells Fargo Market Perform
Nov-18-15Reiterated Oppenheimer Outperform $375 → $375
Nov-11-15Reiterated FBR Capital Mkt Perform $273 → $192
Oct-28-15Downgrade BofA/Merrill Neutral → Underperform
Aug-13-15Initiated Morgan Stanley Underweight $165
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Dec-09-16 05:00PM  Intercept to Present at Upcoming Investor Conference GlobeNewswire
07:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
Dec-05-16 01:05PM  10 Major Pharma and FDA Catalysts Coming in December at 24/7 Wall St.
03:05AM  Intercept Pharmaceuticals Inc (ICPT): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-30-16 12:27PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 30, 2016
Nov-17-16 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
06:59AM  3 Potential Acquisition Targets for Gilead Sciences, Inc. at Motley Fool
Nov-16-16 01:12PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 16, 2016
Nov-14-16 10:19AM  Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-11-16 08:00AM  Intercept Presents New Data at AASLD Examining the Effects of Ocaliva® (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC GlobeNewswire
Nov-09-16 05:09PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report +14.80%
Nov-04-16 09:35AM  Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss
Nov-03-16 06:08PM  Edited Transcript of ICPT earnings conference call or presentation 3-Nov-16 12:30pm GMT -16.46%
09:46AM  Intercept reports 3Q loss
08:56AM  Intercept (ICPT) Reports Narrower-Than-Expected Q3 Loss
08:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q3 2016 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Nov-02-16 04:28PM  Gilead Cuts Losses On NASH Drug, But Liver Is 'Area Of Opportunity'
08:03AM  Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX
Nov-01-16 08:07AM  Intercept (ICPT) Q3 Earnings Preview: What's in the Cards?
07:05AM  Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting GlobeNewswire
Oct-31-16 10:04AM  $40 Billion Opportunity: 3 Biotechs Poised to Dominate at Motley Fool
Oct-28-16 04:05PM  Intercept to Report Third Quarter 2016 Financial Results on November 3 GlobeNewswire
Oct-21-16 04:03PM  Gilead NASH Drug 'Active And Promising,' But Lagging Intercept
12:34PM  Gilead Sciences: These Things Take Time at Barrons.com
Oct-20-16 12:24PM  Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching
08:54AM  Vertex (VRTX) Q3 Earnings: What's in Store for the Stock?
Oct-17-16 09:53AM  Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC
Oct-14-16 12:39PM  Intercept Liver Drug Gets Conditional EU OK (ICPT) at Investopedia
07:36AM  Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the... GlobeNewswire
07:35AM  Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union GlobeNewswire
Oct-13-16 05:22PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:04AM  In Depth Review of Gilead Sciences NASH Pipeline Opportunities
Oct-11-16 04:18PM  Allergan Challenges Intercept With Tobira NASH Drug
Oct-05-16 08:04AM  Allergan Enters the Attractive NASH Market
Oct-04-16 04:23PM  Which Biotechs Set Up For Q4 Boost From Drug Trial Results? -5.77%
11:04AM  Understanding Gilead Sciences NASH Pipeline
Oct-03-16 08:19AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : October 3, 2016
Sep-22-16 11:15PM  Intercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Sold $5.8 million of Shares
04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
10:32AM  Gilead Sciences: A Hidden Asset? at Barrons.com
09:08AM  5 Biotech Stocks to Watch as Interest in NASH Increases
Sep-21-16 12:50AM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal
12:00AM  Big Pharma, Biotech Attack NASH Liver Illness From All Sides at Bloomberg
Sep-20-16 09:40PM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal +8.47%
04:52PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
03:28PM  Biotech buyout: The next big liver disease
01:49PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
01:27PM  Allergan: What is It Thinking?!?! at Barrons.com
12:00PM  Gilead Sciences: Why Allergan's Tobira Purchase is Wonderful, Wonderful News at Barrons.com
11:49AM  Intercept Pharmaceuticals, Inc. Value Analysis (NASDAQ:ICPT) : September 20, 2016
Sep-19-16 08:12AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : September 19, 2016
07:00AM  Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis GlobeNewswire
Sep-12-16 06:16AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Sep-02-16 07:30AM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
Aug-31-16 01:33PM  17 Questions for Gilead Sciences at Barrons.com
Aug-29-16 11:34AM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : August 29, 2016
Aug-26-16 08:16AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : August 26, 2016
Aug-18-16 04:16PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
10:12AM  Intercept (ICPT) Ocaliva Phase III POISE Data Published
Aug-17-16 05:56PM  New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC GlobeNewswire
05:08PM  New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC GlobeNewswire
Aug-09-16 05:19PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
01:43PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : August 9, 2016
Aug-08-16 12:12PM  Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016
10:32AM  Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Aug-05-16 08:56AM  Intercept Pharma downgraded by Laidlaw
Aug-04-16 08:39AM  Intercept (ICPT) Posts Narrower-Than-Expected Loss in Q2 -5.43%
07:51AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:35AM  Intercept reports 2Q loss
07:07AM  Q2 2016 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Aug-02-16 08:26AM  Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?
Aug-01-16 06:36PM  Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Jul-29-16 03:51PM  Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Jul-28-16 07:05AM  Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference GlobeNewswire
Jul-26-16 10:11AM  AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Jul-22-16 05:02PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters t
09:09AM  Trade These 5 Biotech Breakouts Now for Big Gains
Jul-11-16 05:21PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:24AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : July 11, 2016
Jul-09-16 09:02AM  3 Stocks That Could Make You Rich at Motley Fool
Jul-06-16 05:31PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
05:05PM  Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes GlobeNewswire
Jun-30-16 05:21PM  Why Pier 1 Imports, Intercept Pharmaceuticals, and Costamare Slumped Today at Motley Fool
03:16PM  Central bank stimulus talk ignites stocks
09:18AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Convertible Senior Notes GlobeNewswire
Jun-29-16 05:16PM  After The Close: Tractor Supply, Seagate, Google VC, Intercept Pharma
04:15PM  Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes GlobeNewswire
Jun-28-16 05:02PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +14.31%
Jun-27-16 08:39AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : June 27, 2016 -8.57%
Jun-20-16 12:41PM  Cerus Corporation is Surging Today. Here's Why. at Motley Fool
Jun-17-16 12:05PM  Intercept Pharmaceuticals, Inc. Value Analysis (NASDAQ:ICPT) : June 17, 2016
Jun-14-16 08:32AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : June 14, 2016
Jun-13-16 09:06AM  How Are XBIs Holdings Moving Averages Trending?
Jun-10-16 06:03AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
Jun-09-16 05:35PM  Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer GlobeNewswire
Jun-02-16 09:30AM  The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis +8.08%
Jun-01-16 04:05PM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid, a bile acid analog, that completed Phase III clinical trials for the treatment of primary biliary cholangitis and Phase II clinical trials for the treatment of nonalcoholic fatty liver disease; and is in Phase III clinical trials for the treatment of nonalcoholic steatohepatitis, Phase II clinical trials for the treatments of primary sclerosing cholangitis, and Phase II clinical trial for the treatment of biliary atresia. The company is also developing INT-767, an orally administered dual FXR and TGR5 agonist, which is in Phase I clinical trial for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist that is in preclinical stage for the treatment of type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pruzanski MarkCEO & PresidentDec 06Option Exercise28.673,48799,983555,507Dec 08 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 02Sale99.751,350134,66342,922Dec 06 09:00 PM
Bright LisaPresident InternationalNov 25Sale113.6024928,28618,209Nov 29 09:00 PM
Bright LisaPresident InternationalNov 15Sale112.2714015,71818,458Nov 17 09:39 PM
McMinn RachelChief Strategy OfficerOct 31Sale123.8212915,97213,732Nov 02 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 10Sale153.3441163,02344,272Oct 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 03Option Exercise21.501,35029,02546,196Oct 05 09:06 PM
Pruzanski MarkCEO & PresidentOct 03Sale163.20705115,056552,020Oct 05 09:07 PM
Shapiro DavidCMO and EVP - DevelopmentOct 03Sale163.081,513246,73344,683Oct 05 09:06 PM
Duncan Barbara GayleChief Accounting OfficerOct 03Sale163.2014723,99030,661Oct 05 09:04 PM
Bright LisaSee RemarksOct 03Sale163.2015525,29618,305Oct 05 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentSep 26Sale165.083,545585,20044,846Sep 28 09:00 PM
Pruzanski MarkCEO & PresidentSep 20Option Exercise8.9435,000313,054587,725Sep 22 09:00 PM
Pruzanski MarkCEO & PresidentSep 20Sale165.0035,0005,775,000552,725Sep 22 09:00 PM
Bright LisaPresident of InternationalAug 25Sale159.0024639,11418,460Aug 25 09:00 PM
McMinn RachelChief Strategy OfficerAug 01Sale176.5712522,07113,861Aug 02 09:00 PM
Pruzanski MarkCEO & PresidentJul 15Option Exercise9.8212,500122,779560,066Jul 19 09:00 PM
Duncan Barbara GayleChief Accounting OfficerJul 05Sale145.1114621,18630,808Jul 07 09:03 PM
McMinn RachelChief Strategy OfficerJul 05Sale145.1110615,38213,986Jul 07 09:01 PM
Pruzanski MarkCEO & PresidentJul 05Sale145.11714103,608547,566Jul 07 09:02 PM
Bright LisaSee RemarksJul 05Sale145.1115522,49218,706Jul 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 05Sale145.1116323,65348,391Jul 07 09:02 PM
Bright LisaSee RemarksMay 25Sale137.5025134,51218,855May 26 09:00 PM
McMinn RachelChief Strategy OfficerMay 02Sale147.4913019,17414,087May 04 09:00 PM
Pruzanski MarkCEO & PresidentApr 04Sale130.7670892,578548,248Apr 06 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentApr 04Sale130.7616521,57548,546Apr 06 09:02 PM
McMinn RachelChief Strategy OfficerApr 04Sale130.7610413,59914,217Apr 06 09:01 PM
Bright LisaSee RemarksApr 04Sale130.7615320,00619,106Apr 06 09:01 PM
Duncan Barbara GayleChief Financial OfficerApr 04Sale130.7614418,82930,948Apr 06 09:00 PM
Bright LisaSee RemarksFeb 25Sale115.2224127,76819,259Feb 29 09:00 PM
McMinn RachelChief Strategy OfficerFeb 01Sale103.5612813,2567,621Feb 03 09:00 PM
McMinn RachelChief Strategy OfficerJan 04Sale145.9046968,4297,749Jan 05 09:01 PM
Pruzanski MarkCEO & PresidentJan 04Sale145.902,126310,191529,556Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 04Sale145.9053377,76740,911Jan 05 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 04Sale145.9046868,28324,892Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 18Option Exercise17.5011,426199,99139,821Dec 22 10:00 AM
Shapiro DavidCMO and EVP - DevelopmentDec 15Option Exercise8.673,50030,33331,895Dec 17 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 15Sale157.403,500550,90028,395Dec 17 09:00 PM